Toggle Offcanvas
...
 
Everolimus Tenders

Everolimus Tenders

View Everolimus tenders, RFPs and contracts. Bid on readily available Everolimus tenders with the best and most comprehensive tendering platform, since 2002.
Everolimus is an mTOR inhibitor primarily used in cancer treatment and organ transplantation. It helps slow tumor growth and prevents organ rejection by suppressing the immune system.

Bidding for Everolimus tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Everolimus.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Everolimus market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Everolimus tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

19 Live Notices for Everolimus Tenders

Showing 1 to 19

Everolimus Medication Acquisition Oral 0.75 Mg For The Eugenio Espejo Specialties Hospital
country Ecuador
posting date26 Jul 2025
deadline07 Aug 2025
Membekal, Menghantar Dan Menyerah Bekalan Ubat Everolimus 5Mg Tablet Bagi Jabatan Nefrologi Hospital Sultan Ismail Johor Bahru Untuk Tempoh Dua (2) Tahun
country Malaysia
posting date24 Jul 2025
deadline31 Jul 2025
Medicinal Products Iii [2025–2028]
country Czech Republic
posting date23 Jul 2025
deadline26 Aug 2025
Everolimus Pharmaceutical Product 0.75 Mg Tablet - Supply Of The Pharmaceutical Product Everolimus 0.75 Mg Tablet
country Peru
posting date20 Jul 2025
deadline01 Aug 2025
Ruxolitinib Suministro (Doe), Lapatinib (Doe) And Everolumus (Doe)
country Spain
posting date17 Jul 2025
deadline31 Jul 2025
Supply Of Ruxolitinib Medicines (Doe), Lapatinib (Doe) And Everolimus (Doe) For All Osakidetza Service Organizations And Linked Centers.
country Spain
posting date16 Jul 2025
deadline31 Jul 2025
Mcp-Everolimus Hblt System
country Chile
posting date08 Jul 2025
deadline06 Aug 2025
2632A Everolimus And Mykofenolic Acid (Enterotablett)
country Norway
posting date24 Jun 2025
deadline15 Sep 2025
Pharmaceutical Contracts With Accession Option
country Germany
posting date13 Feb 2025
deadline01 Feb 2027
Tender For Securing And Supplying Devices With Solutions And Consumables For Toxicology Laboratories Based On The Fixed Value System For Each Confirmed Result (Gpprr)
country Saudi Arabia
posting date05 Feb 2025
deadline02 Nov 2025
Tender For Securing And Supplying Devices With Solutions And Consumables For Toxicology Laboratories Based On The Fixed Value System For Each Confirmed Result (Gpprr)
country Saudi Arabia
posting date06 Jan 2025
deadline02 Nov 2025
Open House Discount Agreements 2024-03 - Everolimus (Atc: L04Ah02; Tab)
country Germany
posting date15 Feb 2024
deadline31 Oct 2026
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Everolimus, Atc L04Aa18 For The Period February 1St, 2024 - January 31St, 2026
country Germany
posting date18 Dec 2023
deadline05 Dec 2025
Medicines With The Active Ingredient Everolimus (Atc: L04Aa18)
country Germany
posting date12 Dec 2023
deadline30 Nov 2025
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Everolimus (L04Aa18) As Part Of A So-Called Open House Model.
country Germany
posting date11 Oct 2023
deadline30 Sep 2025
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Everolimus (L04Aa18) As Part Of A So-Called Open House Model.
country Germany
posting date10 Oct 2023
deadline30 Sep 2025
Tab./ Cap. Everolimus 0.5 Mg
country India
posting date26 Jul 2025
deadline05 Aug 2025
Everolimus 0.5 Mg (Certican 0.5 Mg) Tablet
country India
posting date24 Jul 2025
deadline27 Aug 2025
Tab Everolimus 0 Point 25Mg,Levo Carnitine 500Mg,Ciprofloxacin Hcl 0 Point 3Parasent Plus Dexametha Quantity: 236510
country India
posting date15 Jul 2025
deadline04 Aug 2025

Share Share this page